Literature DB >> 16827100

A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice.

Kimberly M Palubin1, Bonnie L Goodwin, Melissa I Niesen, Elizabeth A Le, Aaron R Osborne, George Blanck.   

Abstract

BACKGROUND: Tumorigenesis involves the aberrant function of proteins that regulate growth control, including Oct-1. Oct-1 is a DNA binding transcription factor that activates genes that encode proteins required for S-phase and cell growth. For example, Oct-1 activates the histone H2B promoter and the promoters for the snRNPs. Oct-1 also represses certain promoters, including promoters of immune function genes, such as the IL-8 and the HLA-DRA genes. MATERIALS, METHODS AND
RESULTS: Oct-1 antisense transformants were determined to have reduced growth rates and other characteristics of growth control. Also, Oct-1 antisense transformants endured for a shorter time in scid mice, being attributable to the increased expression of IL-8 by the Oct-1 antisense transformants.
CONCLUSION: These results may help resolve the conundrum of why growth control de-regulation alone is not enough for tumorigenicity. The results also support the conclusion that the molecular mechanisms of growth control de-regulation and tumor cell immune functions are directly linked.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827100

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment.

Authors:  Karoly Szekeres; Rudra Koul; James Mauro; Mark Lloyd; Joseph Johnson; George Blanck
Journal:  Exp Mol Pathol       Date:  2014-09-16       Impact factor: 3.362

2.  Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors.

Authors:  Cuiqi Zhou; Yunguang Tong; Kolja Wawrowsky; Serguei Bannykh; Ines Donangelo; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2008-06-11       Impact factor: 5.678

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.